Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2004-001500-13-IT
EUCTR2004-001500-13-IT
Active, not recruiting
Not Applicable

An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the Acute Treatment of DSM-IV Generalized Anxiety Disorder in Outpatients.

PFIZER0 sitesJune 27, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsGeneralized anxiety disorder.MedDRA version: 6.1Level: PTClassification code 10002855
DrugsEFEXOR*14 CPS 75 MG RIL.PROL

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Generalized anxiety disorder.
Sponsor
PFIZER
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 27, 2005
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
PFIZER

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in treating children or adolescents aged 10 to 17 with bipolar depression and if so, how it compares with placebo (a non-active tablet, like a sugar pill, that looks like quetiapine).Health Condition 1: null- Children and Adolescent Subjects With Bipolar Depression
CTRI/2009/091/000696AstraZeneca194
Completed
Not Applicable
A 8 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Human Study for the Evaluation of the Efficacy and Safety of PMEC on Gingival health
KCT0008940MedibioLAB100
Active, not recruiting
Not Applicable
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensio
EUCTR2006-000774-70-GBovartis Pharma Services AG2,252
Active, not recruiting
Not Applicable
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensio
EUCTR2006-000774-70-SEovartis Pharma Services AG2,252
Active, not recruiting
Not Applicable
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioHypertension
EUCTR2006-000774-70-GRovartis Pharma Services AG2,252